Prothena Corporation plc (PRTA)
NASDAQ: PRTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PRTA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $422.10M
- EPS (TTM)
- -$0.45
- Dividend yield
- None
- 52-week range
- 7.70 – 11.80
- Day range
- 8.07 – 8.47
- Volume / Avg
- 861.55K / 487.91K
- Beta
- —
- Shares outstanding
- 51.35M
52-week range
PRTA stock today
Shares of Prothena (PRTA) finished lower on Nov 20 at $8.22, a drop of 2.14% or $0.18 per share, versus the S&P 500's 3.70% decline. Shares are 30.3% below their 52-week high of $11.80, set on May 8, 2026 and 6.8% above the 52-week low of $7.70, near the bottom of the past year's range. PRTA is down 13.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 21.6%.
Prothena has posted a net loss over the last twelve months (EPS of -$0.45), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Prothena
Company profileProthena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Gene G. Kinney Ph.D.
- Headquarters
- Dublin
- Employees
- 67
- Website
- prothena.com
Financial highlights
Full financialsIn fiscal 2025, Prothena generated $9.7 million in revenue, down 92.8% from fiscal 2024, its first annual decline since 2022. Prothena reported a net loss of $244.1 million, compared with a loss of $122.3 million a year earlier. Operating margin was -2216.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $9.68M | $135.16M | $91.37M | $53.91M | $200.58M |
| Growth | -92.83% | +47.92% | +69.50% | -73.13% | +23414.30% |
| Net income | $-244.09M | $-122.31M | $-147.03M | $-116.95M | $66.97M |
| EPS (diluted) | $-4.53 | $-2.27 | $-2.76 | $-2.47 | $1.38 |
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$21.40+160.34%
- Strong buy 2
- Buy 2
- Hold 2
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.32 vs $-0.38
- Surprise
- +15.79%
PRTA news
All PRTA news- Prothena Corporation plc Reports Third Quarter 2026 Financial ResultsNasdaq
- Prothena (PRTA) Reports Q3 Loss, Misses Revenue EstimatesNasdaqPRTA, MRNA
- Prothena Reports Third Quarter 2026 Financial Results and Business HighlightsBusiness Wire
- Bristol Myers Squibb to Terminate PRX019 Global License Agreement with Prothena Corporation plcNasdaq
- Prothena to Report Third Quarter 2026 Financial Results on November 5Business Wire
- Prothena's Partnership Strategy: Growth Driver or Limitation?NasdaqPRTA, BMY, NVO
Prothena peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARVNArvinas Inc. | 6.46 | -4.15% | $423.03M | vs PRTA |
| CRMDCorMedix Inc. | 5.27 | +3.74% | $419.16M | vs PRTA |
| OVIDOvid Therapeutics Inc. | 2.20 | -5.98% | $415.21M | vs PRTA |
| EOLSEvolus Inc. | 6.52 | -6.86% | $431.55M | vs PRTA |
| INDPIndaptus Therapeutics Inc. | 2.82 | -9.90% | $433.16M | vs PRTA |
| AQSTAquestive Therapeutics Inc. | 3.46 | -6.61% | $434.88M | vs PRTA |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs PRTA |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs PRTA |
Indexes, lists and sector
Prothena stock FAQ
What is Prothena's stock price today?
PRTA last traded at $8.22 as of Nov 20, 4:00 PM EST, down 2.14% on the day. Prices are delayed at least 15 minutes.
Who is Prothena's CEO?
Dr. Gene G. Kinney Ph.D. is the chief executive officer of Prothena Corporation plc, which has about 67 employees.
What is the PRTA 52-week high?
The 52-week high for PRTA is $11.80 and the 52-week low is $7.70. The stock is currently 30.3% below its high.